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ABSTRACT The intracellular parasite Toxoplasma gondii resides within a membrane-
bound parasitophorous vacuole (PV) and secretes an array of proteins to estab-
lish this replicative niche. It has been shown previously that Toxoplasma secretes
kinases and that numerous proteins are phosphorylated after secretion. Here, we
assess the role of the phosphorylation of strand-forming protein 1 (SFP1) and
the related protein GRA29, two secreted proteins with unknown function. We
show that both proteins form stranded structures in the PV that are independent
of the previously described intravacuolar network or actin. SFP1 and GRA29 can
each form these structures independently of other Toxoplasma secreted proteins,
although GRA29 appears to regulate SFP1 strands. We show that an unstructured
region at the C termini of SFP1 and GRA29 is required for the formation of
strands and that mimicking the phosphorylation of this domain of SFP1 nega-
tively regulates strand development. When tachyzoites convert to chronic-stage
bradyzoites, both proteins show a dispersed localization throughout the cyst ma-
trix. Many secreted proteins are reported to dynamically redistribute as the cyst
forms, and secreted kinases are known to play a role in cyst formation. Using
quantitative phosphoproteome and proteome analyses comparing tachyzoite and
early bradyzoite stages, we reveal widespread differential phosphorylation of se-
creted proteins. While we found no direct evidence for phosphorylation playing
a dominant role for SFP1/GRA29 redistribution in the cyst, these data support a
model in which secreted kinases and phosphatases contribute to the regulation
of secreted proteins during stage conversion.
IMPORTANCE Toxoplasma gondii is a common parasite that infects up to one-third
of the human population. Initially, the parasite grows rapidly, infecting and destroy-
ing cells of the host, but subsequently switches to a slow-growing form and estab-
lishes chronic infection. In both stages, the parasite lives within a membrane-bound
vacuole within the host cell, but in the chronic stage, a durable cyst wall is synthe-
sized, which provides protection to the parasite during transmission to a new host.
Toxoplasma secretes proteins into the vacuole to build its replicative niche, and pre-
vious studies identified many of these proteins as phosphorylated. We investigate
two secreted proteins and show that a phosphorylated region plays an important
role in their regulation in acute stages. We also observed widespread phosphoryla-
tion of secreted proteins when parasites convert from acute to chronic stages, pro-
viding new insight into how the cyst wall may be dynamically regulated.
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The apicomplexan parasite Toxoplasma gondii is widespread, infecting approxi-mately one-third of the world’s population (1). Although Toxoplasma infection
is predominantly asymptomatic in healthy hosts, complications occur in the immu-
nocompromised, such as cancer and HIV patients, and in pregnant women. In these
patients, infection can cause encephalitis or severely damage the unborn fetus
during pregnancy (2). Additionally, Toxoplasma is a leading cause of retinochoroid-
itis (3), and an expansion of strain diversity in South America is causing substantial
ocular disease (4).
Toxoplasma actively invades nucleated cells of virtually any warm-blooded animal
and subsequently replicates within a membrane-bound parasitophorous vacuole (PV).
During the acute stage of infection, the rapidly growing tachyzoites complete rounds
of invasion and lysis of host cells and disseminate throughout the body. Upon immune
pressure or other stress, the parasite converts to slow-growing bradyzoites that form
cysts, predominantly in skeletal muscle and the brain (5). The cyst is a modified PV with
a protective cyst wall that allows the parasite to establish chronic, perhaps lifelong,
infection of the host.
During infection, Toxoplasma secretes proteins that subvert host cell signaling and
develops its replicative niche within the PV (6, 7). The repertoire of secreted proteins is
thought to include up to 200 proteins (8), including 50 kinases/pseudokinases (9),
although the functions of many of these remain unknown. These proteins are secreted
from the rhoptries or dense granules and are called ROPs or GRAs, respectively.
Secreted proteins extensively modify the PV, allowing the selective passage of mole-
cules and proteins across the PV membrane. For example, GRA17 and GRA23 form
pores in the PV membrane, allowing the passage of small molecules into the PV (10),
while the MYR complex mediates the transport of secreted proteins to the host cell (11,
12). Additionally, the parasite develops a complex set of membrane structures within
the PV, including GRA7-lined invaginations (13) and a network of tubules called the
intravacuolar network (IVN) (14). The formation of this network is dependent on GRA2
and the accessory protein GRA6 and is required for full virulence in mice (15, 16). Both
structures have been reported to play a role in scavenging nutrients from the host cell
with the uptake of host cell proteins (17), lipid droplets (18), and endolysosomal
compartments (19).
A previous phosphoproteome analysis revealed that a large number of Toxoplasma
secreted proteins are phosphorylated after their release (20), raising the intriguing
possibility that their function is dynamically regulated. Indeed, the PV-localized kinase
WNG1 was shown to contribute to the formation of a functional IVN (21). Furthermore,
it was recently shown that IVN-associated GRAs show dynamic localization patterns as
the parasite remodels the PV to form the chronic-stage cyst (22). Here, we analyze two
secreted, strand-forming proteins that are phosphorylated after secretion and show
that their phosphorylated C-terminal tails regulate their localization, disrupting normal
strand formation. Both proteins disperse in chronic-stage cysts, so we hypothesized a
role for phosphorylation and expanded the analysis to compare the phosphopro-
teomes of acute- and chronic-stage parasites. While SFP1/GRA29 dispersion in the
forming cyst appears not to be primarily regulated by phosphorylation, we show that
many GRAs are differentially phosphorylated between these stages, suggesting that the
phosphorylation of secreted proteins may be a key determinant for the dynamic
restructuring of the replicative niche of Toxoplasma.
(This article was submitted to an online preprint archive [23].)
RESULTS
A secreted protein forms strand-like structures in the parasitophorous vacuole
independently of the intravacuolar network and actin. To investigate the role of the
phosphorylation of secreted proteins, we selected TGGT1_289540 as an ideal candi-
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date. It is substantially phosphorylated after secretion (20) and contains a localized
cluster of phosphorylation sites in its C terminus, allowing for targeted genetic mu-
tagenesis. TGGT1_289540 contains a signal peptide and is predicted to localize to the
dense granules (8). It has four predicted coiled-coil domains and an unstructured C
terminus that contains 8 phosphorylation sites (Fig. 1A). Three further phosphorylation
sites are located within the rest of the protein. To first verify that TGGT1_289540 is a
secreted protein, we expressed a myc-tagged version of the protein, which localized to
the PV. Interestingly, in contrast to most GRAs that either are found to fill the space
between parasites or are found associated with the PV membrane, TGGT1_289540
appeared in strand- or filament-like structures (Fig. 1B). Western blotting confirmed the
presence of a single isoform of myc-tagged protein at the predicted size of 100 kDa
in transgenic parasites but not in a wild-type (WT) control (Fig. 1C).
To verify this unusual distribution of TGGT1_289540 in the PV, we generated rabbit
polyclonal antibodies against the recombinant protein. As was the case with the
myc-tagged isoform, analysis of the endogenous protein showed a filamentous distri-
bution in the PV (Fig. 1D). Both the signal detected by immunofluorescence analysis
(IFA) and a band recognized by the antibody in Western blots were absent upon the
disruption of the TGGT1_289540 locus (Fig. 1D and E).
As the Toxoplasma PV contains a distinct IVN of membranous tubules, we tested
whether the strands were related to these structures. The formation of the IVN is
dependent on GRA2, so we assessed TGGT1_289540 localization in RHΔgra2 parasites
that lack the IVN (15). No obvious difference in filamentous TGGT1_289540 localization
was observed (Fig. 1F), indicating that the filaments are distinct from, and their
formation does not depend on, the IVN. We therefore named the protein strand-
forming protein 1 (SFP1 here).
We hypothesized that SFP1 strands could function in transport between the para-
sites and the host cell. Toxoplasma endocytoses proteins from the host cell through an
unknown mechanism (17), so we assessed whether SFP1 plays a role in the uptake of
proteins from the host cell into the parasite at 3 h postinfection. As endocytosed
material is rapidly digested, this can be observed only upon inhibition of cathepsin
protease L function with the inhibitor morpholinurea-leucine-homophenylalanine-vinyl
phenyl sulfone (LHVS) (17). Under these conditions, there was no difference in the
proportions of parasites that had taken up Venus fluorescent protein from the host cell,
indicating that SFP1 does not contribute to protein uptake (see Fig. S1A in the
supplemental material). Toxoplasma upregulates host c-Myc in infected cells, a pheno-
type which is dependent on protein translocation from the PV into the host cell (11, 24).
To test whether SFP1 plays a role in protein export into the host cell, we compared the
abilities of wild-type and Δsfp1 parasites to upregulate host c-Myc. No differences were
observed in host cell c-Myc upregulation, indicating that SFP1 does not play a role in
protein export from the PV (Fig. S1B).
It was recently shown that long filaments of actin extend into the PV from the
parasites during Toxoplasma infection (25). We therefore tested whether treatment with
cytochalasin D, to depolymerize actin, would disrupt SFP1 strand formation. We still
saw substantial filamentation of SFP1 in the presence of cytochalasin D, indicating that
actin is not important in this process (Fig. 1G).
While the presence of the IVN is not important for SFP1 filament formation, the
opposite could be true, that is, that SFP1 may be important for the formation of the IVN.
However, IVN formation was not affected in the absence of SFP1, as shown by
transmission electron microscopy (EM) (Fig. 1H). No obvious abnormalities in the overall
PV organization or PVM structure were observed in RHΔsfp1 parasites.
Collectively, these data indicate that SFP1, a protein that was reported to be
phosphorylated after secretion, localizes to the PV and forms novel, IVN- and actin-
independent filamentous structures. These structures, as suggested by our data, do not
contribute to protein uptake from or protein export into the host cell.
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FIG 1 SFP1 forms strands in the parasitophorous vacuole that are distinct from the intravacuolar network. (A) Schematic
of TGGT1_289540 (SFP1) indicating predicted domains and previously identified phosphosites (shown in blue). SP, signal
peptide; CC, coiled coil. Black lines show predicted unstructured regions. (B) Immunofluorescence images of HFFs infected
with RHΔku80 parasites expressing SFP1-myc. Green, anti-myc antibody; blue, DAPI. (C) Western blot of immunoprecipi-
tated TGGT1_289540::myc. Anti-GRA1 antibodies were used to probe the nonbound fraction as a loading control. (D)
Immunofluorescence images of HFFs infected with RHΔku80 and RHΔsfp1 parasites. Green, polyclonal rabbit anti-SFP1
antibody; blue, DAPI. (E) Western blot analysis of lysates from HFFs infected with RHΔku80 and RHΔsfp1 parasites probed
with rabbit (rb) anti-SFP1 and anti-GRA1 antibodies. (F) SFP1 strands do not depend on GRA2 and the IVN. Immunoflu-
orescence images of RHΔku80- and RHΔgra2-infected HFFs. Green, rabbit anti-SFP1 antibody; blue, DAPI. (G) SFP1 strands
do not depend on actin filamentation. Immunofluorescence images of infected HFFs treated with 1 M cytochalasin D or
the DMSO control. Green, rabbit anti-SFP1 antibody; blue, DAPI. (H) SFP1 is not required for IVN formation. Electron
micrographs of HFFs infected with RHΔku80 and RHΔsfp1 for 16 h. Examples of intravacuolar network tubules are indicated
by arrows.
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A second SFP1-related protein, GRA29, forms related structures. As secreted
protein families can form by gene duplication and diversification, we looked for
potential paralogs of SFP1 in the Toxoplasma genome using BLASTP. We identified a
single protein (TGGT1_269690 [GRA29]) with 24% identity and a similar architecture
(Fig. 2A and Fig. S2) of a signal peptide, coiled-coil domains, and, like SFP1, C-terminal
phosphorylation sites that appear phosphorylated after secretion (20). GRA29 is pre-
dicted to localize to the dense granules (8) and has been shown to be secreted into the
PV (26). To compare the localization of this protein with that of SFP1, we generated a
hemagglutinin (HA)-tagged version, which by IFA localized to the PV, and Western
blotting showed the expected size of 94 kDa (Fig. 2B and C). In contrast to SFP1,
however, we saw smaller filamentous structures and also large puncta associated with
the parasites (Fig. 2B), consistent with the localization reported by Nadipuram et al. (26).
To investigate whether SFP1 and GRA29 were within the same structures, we per-
formed superresolution microscopy using anti-SFP1 antibodies and anti-HA antibodies
to localize GRA29. At this improved resolution, GRA29 puncta appeared as round
spheres or doughnuts, often with SFP1 filaments associated with or branching out from
them (Fig. 2D). We also observed filamentous SFP1 with smaller dots and strands of
GRA29. To further investigate these unusual sphere-like structures, we performed
correlative light electron microscopy (CLEM) to identify the subcellular structures. This
revealed that GRA29::HA accumulates in electron-dense particles in the PV that appear
to contain no membrane and resemble proteinaceous aggregates (Fig. S3).
To verify the GRA29::HA structures, we raised polyclonal antibodies against recom-
binant GRA29. With the antibodies against endogenous protein, we observed only
short strands and small puncta in the PV that did not resemble the HA-tagged parasite
line (Fig. 2E and F). The specificity of the antibodies was verified by Western blotting
and IFA, which showed the expected molecular weight and positive IFA signal in WT
but not in GRA29 knockout (KO) parasites (Fig. 2F and G). This indicates that the
addition of the C-terminal HA tag disrupts GRA29 localization, inducing protein aggre-
gates, suggesting a potentially important role of the C-terminal region. In order to
colocalize endogenous nontagged SFP1 and GRA29, we generated antibodies against
SFP1 peptides in mice, which showed the expected reactivity in IFAs and Western blots
(Fig. 2H and I). The colocalization of SFP1 and GRA29 revealed that both proteins
appear in similar structures, with GRA29 often being present at either end of SFP1
filaments (Fig. 2I).
Collectively, these data show that SFP1 and GRA29 form novel filamentous struc-
tures in the PV. C-terminal tagging of GRA29 alters its localization, either causing or
stabilizing unusual structures that SFP1 can still associate with.
GRA29 regulates SFP1 strand formation even in the absence of other Toxo-
plasma proteins. As SFP1 and GRA29 appeared to localize within the same structures,
we hypothesized that they may show an interdependence. To address this, we localized
SFP1 in the RHΔgra29 parasite line and GRA29 in the RHΔsfp1 parasite line using the
specific antibodies raised. Whereas no alteration in GRA29 was observed in RHΔsfp1,
SFP1 formed fewer and longer filaments in the absence of GRA29 (Fig. 3A). To identify
whether any other Toxoplasma proteins are required for (i) SFP1 filament formation and
(ii) SFP1 filament initiation, we expressed both SFP1 and GRA29, lacking their respective
signal peptides, in human foreskin fibroblasts (HFFs). Both SFP1 and GRA29 formed
long filamentous structures in HFFs (Fig. 3B), often filling the complete cytoplasm and,
in the case of GRA29, sometimes associated with the nucleus. When coexpressed in
HFFs, GRA29 frequently formed smaller puncta and short strands, likely due to the
reduced expression levels of each protein. Strikingly, SFP1 filaments radiated from
GRA29 structures, suggesting that GRA29 can initiate SFP1 strand formation (Fig. 3C).
These data indicate that both SFP1 and GRA29 can each form filament-like struc-
tures independently in the absence of other Toxoplasma proteins. Although we were
unable to confirm the interaction by coimmunoprecipitation from infected cells or with
recombinant proteins (data not shown), the colocalization of SFP1 and GRA29 even in
Phosphorylation in Toxoplasma Stage Conversion















































FIG 2 GRA29 shares homology with SFP1 and forms similar structures in the PV. (A) Schematic of GRA29
indicating predicted domains and previously identified phosphosites (shown in blue). SP, signal peptide;
CC, coiled coil. Black lines show predicted unstructured regions. (B) Immunofluorescence analysis of HFFs
infected with RHΔku80::GRA29-HA. Green, anti-HA antibodies; blue, DAPI. (C) Western blot analysis of
RHΔku80- or RHΔku80::GRA29-HA-infected HFFs with anti-HA and anti-GRA2 antibodies to verify the
expression of HA-tagged protein. (D) Structured illumination microscopy (SIM) of HFFs infected with
RHΔku80::GRA29-HA. Green, anti-HA; magenta, rabbit anti-SFP1; blue, DAPI. (E) SIM analysis of RHΔku80.
Green, anti-GRA29 antibodies; blue, DAPI. (F) Immunofluorescence analysis of HFFs infected with
RHΔku80 and RHΔgra29 parasites. Green, anti-GRA29; blue, DAPI. (G) Western blots of RHΔku80- and
RHΔgra29-infected HFFs probed with anti-GRA29 and anti-GRA2 antibodies. (H) Western blot of
RHΔku80-infected HFFs probed with mouse (ms) anti-SFP1 antibodies generated against the SFP1 C
terminus showing a band of the expected size. (I) SIM analysis of RHΔku80-infected HFFs. Magenta,
mouse anti-SFP1; green, anti-GRA29; blue, DAPI. See also Fig. S3 in the supplemental material.
Young et al.















































this nonphysiological context suggests that they can directly interact. Furthermore, the
localization pattern observed in HFFs and the extended SFP1 filaments in parasites
lacking GRA29 suggest that GRA29 regulates SFP1 strands, perhaps initiating strand
formation or controlling their length.
The SFP1/GRA29 C-terminal tail is required for strand formation. The change of
the localization of GRA29 upon C-terminal HA tagging and the cluster of phosphor-
ylation sites in the C termini of SFP1 and GRA29 suggested that the C-terminal tail
may play an important role in the regulation of strand formation. To address this,
we expressed truncated SFP1 and GRA29 lacking the unstructured C-terminal
FIG 3 GRA29 regulates SFP1 strand formation. (A) Fewer and longer SFP1 strands form in the absence
of GRA29. Immunofluorescence images of HFFs infected with RHΔku80, RHΔsfp1, or RHΔgra29. (Top)
Rabbit anti-SFP1; (bottom) anti-GRA29. Blue, DAPI. (B) SFP1 and GRA29 form strands when ectopically
expressed. Immunofluorescence images of HFFs expressing N-terminally tagged SFP1 (Flag) or GRA29
(HA). Green, anti-Flag or -HA antibodies; magenta, phalloidin to visualize F-actin; blue, DAPI. (C) HFFs
coexpressing Flag-SFP1 and HA-GRA29 show SFP1 strands radiating from GRA29 foci. Immunofluores-
cence images of cotransfected HFFs expressing Flag-SFP1 and HA-GRA29. Green, rabbit anti-SFP1;
magenta, anti-HA; blue, DAPI.
Phosphorylation in Toxoplasma Stage Conversion















































region in HFFs. In contrast to forming filaments under these conditions, both
proteins appeared distributed throughout the HFF cytoplasm, with sparse foci of
aggregation observed (Fig. 4A). This strongly suggested that the C terminus of the
protein plays an important role in filament formation. Consistently, during Toxo-
plasma infection with RHΔsfp1SFP1ΔCt, there was a lack of typical SFP1 strand
formation in the PV (Fig. 4B). However, SFP1ΔCt appeared aggregated within the PV
rather than dispersed, suggesting that other PV-resident proteins impact SFP1
distribution.
Having established that the C terminus of SFP1 is important for its subcellular
organization, we asked whether the phosphorylation of SFP1 is important for filament
formation. To investigate this, we first turned to the expression of phosphomutants in
HFFs, in which all phosphorylation sites in the SFP1 C terminus were mutated to alanine
(SFP1_ALA), and phosphomimetics, in which all phosphorylation sites were mutated to
glutamic acid (SFP1_GLU). While SFP_ALA mutants displayed normal filaments in HFFs,
mimicking phosphorylation led to an inability of SFP1 to form filaments. This indicates
that phosphorylation may be a negative regulator of filament formation (Fig. 4C). This
was replicated when SFP1_ALA and SFP1_GLU were expressed in RHΔsfp1 parasites
(Fig. 4D), where extended strands were observed with phosphomutant but not phos-
phomimetic mutations.
FIG 4 SFP1 and GRA29 C termini regulate strand formation. (A) Immunofluorescence analysis of HFFs expressing
truncated Flag-SFP1 or HA-GRA29 lacking its disordered C terminus. Green, anti-Flag or -HA antibodies; magenta,
phalloidin to visualize F-actin; blue, DAPI. (B) SIM analysis of HFFs infected with RHΔsfp1 expressing SFP1-myc or
SFP1ΔCterm-myc. Green, rabbit anti-SFP1 antibodies; blue, DAPI. (C) SFP1 phosphomutants (preventing phosphor-
ylation) do not disrupt strand formation. Immunofluorescence analysis of HFFs expressing Flag-SFP1 or Flag-SFP1
with the C-terminal phosphosites mutated to Ala or Glu. Green, anti-Flag antibodies; blue, DAPI. (D) Immunoflu-
orescence analysis of HFFs infected with RHΔsfp1 expressing myc-tagged SFP1, SFP1_ALA, or SFP1_GLU. Green,
anti-myc antibodies; blue, DAPI.
Young et al.















































If phosphorylation was preventing filament formation, we hypothesized that SFP1
expressed in HFFs should not be phosphorylated. To verify that assumption, we
immunoprecipitated SFP1 from HFFs and analyzed the proteins by mass spectrometry
(MS). Despite the presence of many nonmodified peptides from SFP1, we observed no
phosphopeptides (data not shown), indicating that, indeed, SFP1 is not phosphorylated
by human kinases when expressed in HFFs.
Collectively, these data show that the C termini of SFP1 and GRA29 are important for
their regulation and that the phosphorylation of SFP1 appears to be a negative
regulator, with the nonphosphorylated protein forming strands.
SFP1 and GRA29 are dispersed and do not form strands in chronic-stage cysts.
To determine whether SFP1 and GRA29 are required in vivo, we generated gene KOs
in the type II strain Pru and verified gene disruption by Western blotting (Fig. S4A).
Mice infected with PruΔsfp1 and PruΔgra29 parasites succumbed to infection
similarly to WT PruΔku80 parasites, indicating that neither protein is essential for
parasite survival in vivo (Fig. S4B and C). During our experiments with the Pru
strains, we observed that in some vacuoles, SFP1 and GRA29 appeared distributed
throughout the PV space instead of forming characteristic strands (Fig. 5A). Type II
strains differ from the type I RH strain in that they more frequently convert to
slow-growing bradyzoites in tissue culture. Bradyzoite cysts can be distinguished
from tachyzoite vacuoles using fluorescently labeled lectin (Dolichos biflorus agglu-
tinin [DBA]) that binds to the cyst wall (27). Parasites with a disperse SFP1/GRA29
pattern also stained positive for the cyst wall marker (Fig. 5A). Spontaneous
conversion to bradyzoites occurs at low levels in standard tissue culture, but high
levels of conversion can be induced by pH stress (28). Under bradyzoite-inducing
conditions, parasite vacuoles were positive for the cyst wall marker CST1 and
FIG 5 SFP1 and GRA29 disperse in chronic-stage cysts. (A) Immunofluorescence analysis of HFFs infected
with PruΔhxgprt for 40 h. Green, rabbit anti-SFP1 or anti-GRA29; red, DBA to stain the cyst wall; blue,
DAPI. (B) Immunofluorescence analysis of PruΔhxgprt-infected HFFs grown under bradyzoite-inducing
conditions for 3 days. Green, rabbit anti-SFP1 or anti-GRA29; magenta, anti-CST1 to visualize the cyst wall;
blue, DAPI.
Phosphorylation in Toxoplasma Stage Conversion















































showed disperse SFP1 and GRA29, indicating that both proteins undergo a major
change in localization between the tachyzoite and bradyzoite stages (Fig. 5B).
Secreted proteins are differentially phosphorylated in the chronic stage. We
hypothesized that increased phosphorylation of SFP1 and GRA29 under bradyzoite
conditions could lead to their dispersion. This phenomenon of redistribution in the
bradyzoite cyst has been described previously for other GRAs (22, 29), and so we wanted
to determine if these were also differentially phosphorylated. We therefore used
comparative phosphoproteomics to determine differences in the phosphorylation of
SFP1 and GRA29 and, more broadly, between acute (tachyzoite) and chronic (brady-
zoite) conditions. Triplicate samples of Toxoplasma parasites were grown under
tachyzoite conditions for 27 h or bradyzoite conditions for 3 days (to give comparable
numbers of parasites per vacuole) (Fig. 6A). We performed quantitative mass spectrom-
etry to compare protein and phosphosite abundances under the two conditions using
tandem mass tags (TMTs) as described previously (30, 31). First, we analyzed differential
FIG 6 Secreted proteins are differentially phosphorylated in acute and chronic stages. (A) Schematic of the quantitative phosphoproteomics experiment.
Peptides from triplicate tachyzoite and bradyzoite samples were labeled with tandem mass tags (TMTs), enriched for phosphopeptides, and analyzed by mass
spectrometry. (B) Volcano plot showing differential phosphorylation between tachyzoite and bradyzoite conditions after normalization to protein abundance.
Each circle represents a phosphosite, and those that change significantly (FDR, 1%; 0.9  log2-fold change  0.9) are shown in green. (C) Dense granule
proteins are enriched in the subset of proteins that show significantly changing phosphorylation between tachyzoites and bradyzoites. The chart shows the
predicted localization of phosphoproteins using LOPIT (8). PM, plasma membrane; IMC, inner membrane complex; ER, endoplasmic reticulum.
Young et al.















































protein abundances and identified 171 differentially regulated proteins, with 103
proteins with higher abundances in bradyzoites and 68 with higher abundances in
tachyzoites. As expected, known bradyzoite markers such as BAG1, ENO1, LDH2, and
MAG1 were more abundant in the bradyzoite samples than in the tachyzoite samples
(Data Set S1 and Fig. S5).
In the phosphopeptide-enriched samples, we quantified 7,650 phosphorylation sites
on 2,235 Toxoplasma proteins. For 3,730 of the phosphorylation sites, we also obtained
quantitative proteome data to which phosphorylation site changes were normalized.
This allowed us to assess true differential phosphorylation rather than changes origi-
nating from differential protein abundances between conditions. After this normaliza-
tion step, we identified 337 phosphorylation sites that were significantly different
between tachyzoite (144 sites more phosphorylated) and bradyzoite (193 sites more
phosphorylated) stages (Fig. 6B and Data Set S1). The 337 phosphorylation sites are
found on 170 proteins, 51 of which are predicted to be secreted (ROPs or GRAs in the
LOPIT data set [8]). While GRAs made up 11% of proteins with nonchanging phospho-
sites, they represented 26% of differentially phosphorylated proteins (Fig. 6C). This
enrichment of GRAs in the subset of proteins that are differentially phosphorylated
between tachyzoite and bradyzoite conditions indicates that these are indeed subject
to extensive differential phosphorylation during stage conversion.
In this experiment, we also identified phosphosites corresponding to the C termini
of SFP1 and GRA29, but they did not significantly change between conditions (al-
though a previously undetected N-terminal site on GRA29 was detected as more
phosphorylated in bradyzoites). This indicates that while mimicking phosphorylation
disrupts SFP1 strands in the PV in tachyzoites, this modification is not sufficient for the
dispersion observed in the forming cyst. However, the GRAs that were detected as
differentially phosphorylated included IVN-localized GRA2, GRA4, GRA6, and GRA12 and
PV membrane GRA1 and GRA5 (Table 1). We also detected differential phosphorylation
of the cyst wall proteins CST1, CST3, CST4, and CST6. Furthermore, of the 38 recently
identified putative cyst wall components (32), 24 were differentially phosphorylated,
suggesting that phosphorylation could play an important role in the formation of this
structure.
It is worth noting that we also observed differential phosphorylation on proteins
important for DNA regulation. This includes the AP2 domain transcription factors
AP2VIII-2 and AP2XII-4 and 32 predicted nuclear proteins. These may be important for
transcriptional regulation during stage conversion, but their role is not further dis-
cussed here.
Collectively, these data show that SFP1 and GRA29 undergo a dramatic change in
localization between tachyzoite and bradyzoite conversion but that their phosphory-
lation is transient or not required for this transition, at least at the experimental time
point selected here. Furthermore, we show widespread changes in phosphorylation
states in a substantial number of secreted proteins, indicating the activity of stage-
specific kinases and phosphatases in regulating PV-resident proteins.
DISCUSSION
Here, we have analyzed the localization of two secreted phosphoproteins, SFP1 and
GRA29, that relocalize during stage conversion to bradyzoites. Both proteins form
stranded structures in the tachyzoite PV that are distinct from the IVN and actin
filaments previously observed. We did not identify a function of SFP1 and GRA29 during
the lytic cycle or in vivo infections, preventing us from assessing the impact of their
phosphorylation on Toxoplasma biology. It could be that the proteins have a subtle
effect on growth that we have not been able to measure or that they are important in
another host species, parasite stage, or genetic background that we have not tested
here. However, neither SFP1 nor GRA29 showed a reduction in fitness in vivo (33) in our
recent more sensitive in vivo CRISPR screen, supporting a nonessential role under these
conditions.
We show the importance of the C termini of both proteins for strand formation.
Phosphorylation in Toxoplasma Stage Conversion















































TABLE 1 Differential phosphorylation of predicted dense granule proteins between
tachyzoites and bradyzoitesa
Protein ID
Protein annotation/name from ToxoDB
comments
Proteome T vs B LFCPhosphosite position T vs B LFC
























TGME49_267740 Hypothetical protein 0.51
195 1.67
196 1.08





TGME49_263220 Rhoptry kinase family protein ROP21 0.43
246 1.07




TGME49_240060 Hypothetical protein/TgIST 0.41
486 1.03
550 1.56
TGME49_247440 Hypothetical protein/GRA33 0.37
68 0.98
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Protein annotation/name from ToxoDB
comments
Proteome T vs B LFCPhosphosite position T vs B LFC







TGME49_288650 Dense granule protein GRA12 0.24
415 1.94
TGME49_269690 Hypothetical protein/GRA29 0.24
46 1.49









TGME49_230705 Hypothetical protein/GRA51/CST3 0.20
72 0.97
TGME49_289380 Hypothetical protein/GRA39 0.16
326 1.55
TGME49_270250 Dense granule protein GRA1 0.09
186 0.96
TGME49_254720 Dense granule protein GRA8 0.01
198 1.10
TGME49_200360 Hypothetical protein 0.01
152 1.23
















TGME49_201130 Rhoptry kinase family protein ROP33 0.21
394 1.05
TGME49_225160 Hypothetical protein 0.22
391 1.12
(Continued on next page)
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Using mutational analysis, we show that SFP1 phosphorylation is not required for
filament formation and that mimicking phosphorylation disrupts filament formation. As
such, mimicking phosphorylation mirrored the phenotype observed with the removal
of the C-terminal tail. Phosphorylation negatively regulates the intrinsic behavior of
SFP1 and abrogates its ability to form strands. However, as both SFP1 and GRA29 were
identified to be phosphorylated after secretion into the PV (20), where, as we show
here, they form fibril-like structures, we assume that their phosphorylation is a dynamic
process, potentially leading to the regulation of their length and location. It could also
be that phosphorylated and nonphosphorylated SFP1 and GRA29 localize to different
structures in the PV. How both proteins relocalize during stage conversion is unclear.
While mimicking phosphorylation appears sufficient to promote the dispersal of SFP1
HFFs, this is not observed when expressed in tachyzoites, where aggregation is
observed. This indicates that other proteins or posttranslational modifications are
involved in SFP1 regulation in parasites upon stage conversion.
Recently, the PV-localized kinase WNG1/ROP35 was shown to phosphorylate
several GRAs, including GRA6, and to regulate their membrane association (21). As
many GRAs form complexes during trafficking (34), WNG1 phosphorylation is
hypothesized to release them from association with a chaperone, freeing them to
associate with membranes. As such, WNG1-dependent phosphorylation of GRAs
was shown to promote their normal behavior and localization. We now propose
TABLE 1 (Continued)
Protein ID
Protein annotation/name from ToxoDB
comments
Proteome T vs B LFCPhosphosite position T vs B LFC





TGME49_247530 Hypothetical protein 0.40
53 1.12




TGME49_278770 Hypothetical protein 0.50
220 1.11
TGME49_275470 Dense granule protein GRA15 0.58
521 1.10
TGME49_231960 Omega secalin, putative/GRA28 0.65
1208 1.89
1789 1.19





TGME49_279100 Hypothetical protein/MAF1a 0.71
48 1.39
62 1.20
aShown is a subset of the data in Data Set S1 in the supplemental material showing proteins predicted to
localize to the dense granules with a log2-fold change (LFC) in protein abundance of 1. Log2-fold changes
for the proteome and the normalized LFCs for each phosphosite are shown. Negative scores indicate
enrichment in bradyzoites. For full details, see Data Set S1. T, tachyzoites; B, bradyzoites.
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that in addition to WNG1 phosphorylation promoting the release and membrane
association of GRAs, the phosphorylation of secreted proteins can negatively
regulate their behavior. In this way, the parasite could use phosphorylation by
kinases within the PV lumen to regulate PV-resident proteins. This would allow the
parasite to tailor its niche and respond to differing conditions or requirements.
Several secreted kinases localize within the PV lumen and are upregulated during
the chronic stages of infection (for example, ROP21, ROP27, ROP28, and, indeed,
WNG1/ROP35). Importantly, secreted kinases have been shown to contribute to cyst
formation in mice, indicating that phosphorylation within the PV/forming cyst is
required for cyst development. ROP21/27/28 contribute to the parasite establishing
chronic infection, but their function and targets remain unknown (35). Additionally, a
triple knockout of ROP38/29/19 showed a severe defect in cyst formation (36). Here, we
expand our knowledge of cyst formation by reporting the differential phosphorylation
of proteins within the forming cyst. Our data also identify phosphorylation that is
reduced upon stage conversion. The expression of many ROP family kinases is reduced
in the chronic stage of infection, which could account for some changes, but it is likely
that secreted phosphatases are contributing to the differential phosphorylation. The
necessity of deleting several ROPs to observe strong phenotypic effects on bradyzoites
may reflect that the system is flexible with a high degree of redundancy. Alternatively,
the combined effect of multiple kinases could allow the parasite to integrate several
signals leading to stage differentiation.
PV-resident GRAs relocalize as the parasite converts to the chronic stage and
remodels the PV to form a cyst. Guevara et al. recently described the dynamic nature
of this relocalization over the course of cyst formation (for GRA1, -2, -4, -6, -9, and -12)
(22). Furthermore, they showed that IVN-localized GRAs were required for normal
formation of the cyst wall. Here, we show that these GRAs, with the exception of GRA9
(which is upregulated in bradyzoites), are differentially phosphorylated in the acute and
chronic stages, suggesting that phosphorylation could play a role in their regulation.
Interestingly, GRA2 showed phosphorylation sites that were enriched under each
condition; two sites within a predicted amphipathic helix were more phosphorylated
under tachyzoite conditions, while a third site was more phosphorylated in the brady-
zoite samples. It is tempting to speculate that dual phosphorylation within the polar
side of the amphipathic helix (a1) of GRA2 could alter its membrane binding. Further
work assessing the phosphorylation of secreted proteins over time is required to
decipher the impact of this modification and the role of both kinases and phosphatases
in remodeling the PV. However, the regulation of proteins after parasite secretion adds
an intriguing extra layer of complexity to pathogen effector biology and the establish-
ment of Toxoplasma chronic infection.
MATERIALS AND METHODS
Cell culture and parasite strains. Primary human foreskin fibroblasts (HFFs) (ATCC) were maintained
in Dulbecco’s modified Eagle’s medium (DMEM) with 4.5 g/liter glucose and GlutaMAX-1 (Gibco)
supplemented with 10% fetal bovine serum (FBS) at 37°C with 5% CO2. T. gondii RHΔku80::diCre (37),
RHΔgra2 (38), PruΔku80 (39), and PruΔhxgprt (gift from Dominique Soldati) (40) parasites were main-
tained by growth in confluent HFFs and passaged every 2 to 3 days. RH strains were seeded 24 h, and
Pru strains were seeded 48 h, before transfections or infection experiments.
Sequence analysis. Gene sequences and predicted protein localizations (LOPIT data set) were
obtained from ToxoDB. Alignments were generated using ClustalW, and schematics were generated
using DOG2.0 (41). Protein sequences were analyzed by Multicoil2 (42) and Globplot (43) to identify
coiled-coil and unstructured regions, respectively.
Plasmid construction. All primers are shown in Table S1 in the supplemental material. Vectors were
generated by inverse PCR using KOD hot-start polymerase (Novagen) or by Gibson assembly in a
homemade reaction master mix (100 mM Tris-Cl [pH 7.5], 50 mg/ml polyethylene glycol 8000 [PEG 8000],
10 mM MgCl2, 10 mM dithiothreitol [DTT], 0.2 mM [each] four deoxynucleoside triphosphates [dNTPs], 1
mM NAD with 0.8 U T5 exonuclease [NEB], 0.5 U Phusion DNA polymerase [NEB], and 80 U Taq DNA ligase
[NEB]). Gibson reaction mixtures were incubated for 60 min at 50°C. All vectors were verified by
sequencing. sfp1 and gra29 sequences were amplified from Toxoplasma genomic DNA (gDNA) prepared
from 1E7 RHΔku80::diCre parasites using a Qiagen blood and tissue DNA extraction kit, unless otherwise
stated.
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To generate pSFP1, the TGGT1_289540 promoter and coding sequence were amplified using primers
1 and 2 and inserted into HindIII/PacI-digested pGRA (13). A C-terminal myc tag was inserted by inverse
PCR using primers 3 and 4. pSFP1ΔCterm, which lacks residues 863 to 937, was generated by inverse PCR
on pSFP1 with primers 4 and 5. To generate phosphomutant versions of pSFP1, initially, a silent ApaI site
was inserted into pSFP1 (at nucleotide [nt] 2529) by inverse PCR with primers 6 and 7. Four-hundred-
base-pair synthetic DNA fragments (IDT) (Text S1) encoding the SFP1-myc C terminus or versions with
Ser/Thr-to-Ala or Ser/Thr-to-Glu mutations were mixed with ApaI/PacI-digested pSFP1 ApaI in Gibson
reaction mix. The sites mutated to Ala or Glu were S862, S868, S871, S887, S891, S897, S906, S913, S924,
and T933. pGRA29-HA was generated by amplifying the GRA29 promoter and coding sequence using
primers 8 and 9 and inserting the amplicon into HindIII/NcoI-digested pGRA.
For pcDNA-NTAP-Flag SFP1 constructs, the SFP1 coding sequence excluding the signal peptide
(amino acids 1 to 53) was amplified with primers 10 and 11 for full-length or primers 10 and 12 for
C-terminally truncated (lacking amino acids 863 to 937) versions. For phosphosite mutant versions,
primers 10 and 11 were used with pSFP1_ALA or pSFP1_GLU as the template. All amplicons were
inserted into NotI/EcoRI-digested pcDNA-NTAP, a pcDNA3.1 derivative for expression with a 3 Flag tag,
a tobacco etch virus (TEV) cleavage site, and a calmodulin binding peptide. For the pcDNA-HA-GRA29
construct, GRA29 lacking its predicted signal peptide (residues 1 to 25) was initially amplified with
primers 13 and 14 and inserted into NotI/EcoRI-digested pcDNA-NTAP. The Flag tag was removed, and
an N-terminal HA tag was inserted by inverse PCR with primers 15 and 16. pcDNA-GRA29ΔCterm, lacking
residues 771 to 865, was generated by inverse PCR with primers 17 and 18.
Guide RNA (gRNA) sequences targeting the 5= and 3= ends of sfp1/gra29 were inserted into
pSAG1::CAS9-U6::gUPRT (44) by inverse PCR with primers 19 and 20 to 23. Dual gRNA pSAG1::CAS9
vectors were generated by amplifying the 3= gRNA expression locus with primers 24 and 25 and inserting
the region into XhoI/PacI-digested pSAG1::CAS9 carrying the 5= gRNA.
To generate the SFP1 bacterial expression plasmid pET-28a-SFP1, SFP1 lacking its amino-terminal
signal peptide was amplified using primers 26 and 27. The amplicon was cloned into the BamHI- and
NdeI-digested pET-28a() plasmid (Merck).
Parasite transfection. Parasites were released from HFFs by syringe lysis, pelleted at 650  g, and
resuspended in cytomix (10 mM KPO4, 120 mM KCl, 0.15 mM CaCl2, 5 mM MgCl2, 25 mM HEPES, 2 mM
EDTA). Approximately 5E6 parasites were combined with 40 g DNA in 400 l cytomix in a 2-mm cuvette
and electroporated using a Bio-Rad Gene Pulser Xcell instrument at 1,500 V and 25 F. Repair templates
were linearized by overnight digestion, purified by phenol-chloroform precipitation, and resuspended in
H2O. At 24 h posttransfection, 50 g/ml mycophenolic acid (Merck) and xanthine (Sigma) (M/X) was
added to select for transfectants.
Generation of parasite lines. RHΔku80 lacking SFP1 was generated by transfecting parasites with
pSAG1-CAS9gSFP1 targeting the 5= end of the gene (starting 84 nt after ATG) with a 183-nt repair
template to remove the protospacer-adjacent motif (PAM) site and introduce stop codons (Text S1).
Parasites expressing the transfected Cas9-green fluorescent protein (GFP) were sorted by flow cytometry
into 96-well plates containing HFF monolayers using a BD Influx cell sorter (BD Biosciences). This line was
used for complementing pSFP1myc constructs. Alternatively, gra29 and sfp1 were disrupted in the
RHΔku80 and PruΔku80 backgrounds by cotransfecting a double gRNA pCAS9 vector targeting the 5=
and 3= ends of the gene and a synthetic repair construct with 500-nt homology arms and a
hypoxanthine-xanthine-guanine phosphoribosyl transferase (HXGPRT)-thosea asigna virus 2A (T2A)-
mCherry cassette (GeneArt; Life Technologies). Transfectants were selected by the addition of M/X, and
clones were screened by immunofluorescence and verified by Western blotting.
Antibody generation. N-terminally 6His-tagged SFP1 recombinant protein was expressed from
pET-28a-SFP1 in Escherichia coli BL21 cells. His-SFP1 was purified using Ni-nitrilotriacetic acid (NTA)
affinity purification under native conditions according to the standard manufacturer’s protocol (Qiagen).
Recombinant His-SFP1 was used to immunize female New Zealand White rabbits (Covalab) for the
generation of polyclonal antibodies. To generate the mouse anti-SFP1 antibody, phosphopeptides
corresponding to the C terminus of SFP1 were conjugated to keyhole limpet hemocyanin and used to
immunize 4 mice (Covalab). Day 53 sera showed reactivity against SFP1. While mice were immunized
with phosphorylated isoforms, the antibodies recognize nonphosphorylated peptides.
The following SFP1 peptides were used for immunization (residues in boldface type are phos-
phorylated): NH2-C-GSVASGFRG-CONH2, NH2-C-GFRGSMASGLFP-CONH2, NH2-C-LRGASVAGSLGG-
CONH2, NH2-C-GGVGSRLGG-CONH2, and NH2-C-FAGASMGRG-CONH2.
Immunoprecipitation. HFFs were infected with RHΔku80 or RHΔku80SFP1::myc in a T25 flask for
24 h before lysis in 1 ml radioimmunoprecipitation assay (RIPA) buffer (Thermo Scientific) supplemented
with protease (complete mini; Roche) inhibitors. Samples were clarified by centrifugation and incubated
with anti-myc tag antibody-conjugated agarose (catalog no. 16-219; Millipore) for 3 h. The nonbound
fraction was removed, and the proteins were precipitated with acetone at 20°C. Agarose bead
complexes were washed in RIPA buffer followed by Tris-buffered saline, and proteins were eluted by
boiling in Laemmli buffer (60 mM Tris-HCl [pH 6.8], 1% sodium dodecyl sulfate [SDS], 5% glycerol, 5%
-mercaptoethanol, 0.01% bromophenol blue).
Western blotting. Toxoplasma lysates or immunoprecipitation (IP) samples were separated by
SDS-polyacrylamide gel electrophoresis (PAGE), transferred onto nitrocellulose (Bio-Rad), and probed
with appropriate antibodies in phosphate-buffered saline (PBS) with 3% milk and 0.1% Tween 20
(Sigma-Aldrich). Rabbit and mouse anti-SFP1 sera were used at a dilution of 1:1,000, rabbit anti-GRA29
serum was used at 1:1,000 (33), mouse anti-GRA1 was used at 1:1,000 (gift from Jean-Francois
Dubremetz), mouse anti-GRA2 was used at 1:1,000 (catalog no. BIO.018.5; Biotem), mouse anti-Myc was
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used at 1:1,000 (catalog no. 05-724; Millipore), and rat anti-HA was used at 1:1,000 (catalog no.
11867423001; Roche). After washing, the blots were incubated with horseradish peroxidase (HRP)-
conjugated secondary antibodies, anti-rabbit at 1:20,000 (catalog no. 474-1506; Insight Biotechnology),
anti-mouse at 1:3,000 (catalog no. 474-1506; Insight Biotechnology), or anti-rat at 1:4,000 (catalog no.
629520; Life Technologies). The blots were visualized using ECL Western blotting detection reagent (GE
Healthcare) for chemiluminescence imaging on an Amersham Imager 600 instrument (GE Healthcare).
Parasite infections. For wide-field, confocal, or EM imaging, HFFs were seeded on 13-mm no. 1.5
coverslips in 24-well plates. Confluent monolayers were infected at a multiplicity of infection (MOI) of 1
for 16 to 24 h. For cytochalasin D treatment, infected cells were incubated with 1 M cytochalasin D or
dimethyl sulfoxide (DMSO) for 1 h before fixation. Samples were washed with PBS before fixation in 3%
formaldehyde (FA) for 15 min. For EM analysis, infected cells were fixed in 4% FA for 15 min followed by
2.5% glutaraldehyde– 4% FA for 30 min and storage in 1% FA.
Conversion to bradyzoites. To induce parasite switching to bradyzoites, HFF monolayers were
infected at an MOI of 0.5 for 3.5 h and then washed four times with PBS before the addition of switch
medium (RPMI 1640 [catalog no. R4130; Sigma] with 1% FBS [pH 8.1]) and incubation at 37°C with
ambient CO2 for 3 days. Cells were fixed in 3% FA, quenched in 50 mM ammonium chloride, and
permeabilized in a solution containing 0.2% Triton X-100, 0.1% glycine, and 0.2% bovine serum albumin
(BSA) in PBS for 20 min on ice.
Intracellular fluorescent-protein ingestion assay. Intracellular fluorescent-protein ingestion was
assessed as described previously by McGovern et al. (45). Briefly, 70 to 80% confluent CHOK1 cells were
transfected in 35-mm dishes using X-TremeGENE 9 transfection reagent (catalog no. 6365787001; Roche).
Each dish was transfected with 2 g of the pcDNA 3.1 Venus plasmid using a 3:1 ratio of plasmid to
transfection reagent in OptiMEM (catalog no. 31985062; Gibco) and a total final volume of 200 l. The
CHO K1 cells were then incubated overnight at 37°C and synchronously infected with T. gondii parasites
using the Endo buffer method at 18 to 24 h posttransfection (46). T. gondii parasites were treated with
1 M LHVS or an equal volume of DMSO for 48 h prior to synchronous invasion, replacing the LHVS- and
DMSO-treated media every 6 to 18 h, and also during the 3-h incubation period after synchronous
invasion. T. gondii parasites were purified at 3 h postinvasion as previously described (17), pelleted by
centrifugation at 1,000  g for 10 min at 4°C, and subjected to a protease protection assay by resus-
pension in 250 l of freshly prepared 1 mg/ml pronase (catalog no. 10165921001; Roche)– 0.01%
saponin–PBS at 12°C for 1 h. The parasites were then pelleted by centrifugation at 1,000  g for 10 min
and washed 3 times in ice-cold PBS before depositing them on CellTak (catalog no. 354240; Corning)-
coated chamber slides. Parasites were fixed with 4% paraformaldehyde and imaged with an AxioCam
MRm cameraequipped Zeiss Axiovert Observer Z1 inverted fluorescence microscope. Ingestion of host
cytosolic Venus was scored manually as Venus positive or Venus negative without sample blinding.
HFF transfection. HFFs were seeded at a density of 7.5  104 cells per well on a 13-mm glass
coverslip 24 h before transfection with Lipofectamine 2000 (Thermo Fisher). For each well, 1.5 l
Lipofectamine 2000 was mixed with 800 ng plasmid DNA in 100 l Opti-MEM (Thermo Fisher). Cells were
fixed in 3% FA at 18 h posttransfection.
Immunofluorescence analysis. For immunofluorescence analysis, cells were quenched in 50 mM
ammonium chloride for 15 min. For transfection experiments and initial RHΔku80SFP1::myc or
RHΔku80GRA29::HA infections, samples were permeabilized for 3 min in 0.1% Triton X-100 and blocked
with 2% BSA in PBS. For subsequent infection experiments, samples were permeabilized and probed in
a solution containing 0.05% saponin and 0.2% fish gelatin in PBS. Infected or transfected cells were
probed with mouse anti-myc (1:1,000) (catalog no. 05-724; Millipore), rat anti-HA (1:1,000) (catalog no.
11867423001; Roche), mouse anti-Flag (1:1,000) (catalog no. F1804; Sigma), rabbit anti-GRA29 (1:4,000)
(33), rabbit anti-SFP1 serum (1:1,000), mouse anti-SFP1 (1:200), or mouse anti-CST1 (1:100) (gift from
Louis Weiss), followed by Alexa Fluor 488- or 564-conjugated secondary antibodies (1:2,000) (Life
Technologies). Additionally, cells were labeled with 4=,6-diamidino-2-phenylindole (DAPI) (1:1,000 dilu-
tion of 5 mg/ml) (Sigma-Aldrich), Alexa Fluor 647-conjugated phalloidin (1:100) (catalog no. A22287;
Invitrogen), or rhodamine-conjugated Dolichos biflorus agglutinin (1:200) (catalog no. RL-1302; Vector
Labs). Antibodies/stains were diluted in 2% BSA–PBS, samples were incubated for 1 h, and coverslips
were subsequently washed and mounted with ProLong Gold antifade mountant (catalog no. P36934;
Thermo Fisher). Localizations were visualized on a Nikon Ti-E microscope or a Leica SP5 confocal
microscope.
Superresolution microscopy. For superresolution microscopy, 24- by 24-mm no. 1.5H coverslips
were washed in 1 M HCl overnight and rinsed in water before coating with 1% (wt/vol) porcine gelatin
(catalog no. G1890; Sigma) in 6-well plates. Confluent HFF monolayers were infected at an MOI of 0.5 and
centrifuged at 180  g for 3 min to synchronize infection. Samples were fixed and processed as described
above except that antibody dilutions were passed through 0.45-m filters and an additional final fixation
step (10 min, 2% FA) was included after secondary antibody incubation. Superresolution microscopy
imaging was performed using an OMX v3 structured illumination microscope (Applied Precision/GE
Healthcare) equipped with 405-, 488-, and 592.5-nm diode lasers; electron-multiplying charge-coupled-
device (CCD) cameras (Cascade II 512 by 512; Photometrics); and a 100/1.40-numerical-aperture (NA)
PlanApochromat oil immersion lens objective (Olympus). Three-dimensional structured illumination
microscopy (3D-SIM) image stacks were reconstructed and aligned using softWoRx (Applied Precision/GE
Healthcare).
Correlative light and electron microscopy. HFFs were seeded on a 3.5-cm dish with a gridded
coverslip (MatTek) and infected, fixed, and processed as described above. Regions of interest with
GRA29-HA cage structures were selected and imaged by SIM. Tiled images of the surrounding area were
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generated by confocal imaging to aid in identifying the region by EM. The cells were then fixed and
prepared for EM as described below. The light and electron microscopy overlay was generated by using
the TurboReg plug-in of Fiji software, with an affine transformation using the parasite nuclei and
apicoplasts as landmarks, and by selecting high-intensity pixels in Photoshop using the magic wand tool
with tolerance set to 40.
EM sample preparation and imaging. Cells were fixed in a solution containing 2.5% glutaraldehyde
and 4% formaldehyde in 0.1 M phosphate buffer (PB) at room temperature (RT) for 30 min, postfixed in
1% reduced osmium tetroxide for 1 h, stained with 1% tannic acid in 0.05 M PB for 45 min, and quenched
with 1% sodium sulfate in 0.05 M PB for 5 min. For CLEM experiments, the gridded coverslip was then
removed from the MatTek dish. After washing in PB and water, the cells were dehydrated in 70, 90, and
100% ethanol (twice for 5 min each) before infiltration with a 1:1 mix of propylene oxide and Epon resin
(Taab Embed 812) for 1 h and then twice for 90 min with Epon resin. Finally, coverslips were embedded
in resin for 24 h at 60°C, sectioned (70 to 75 nm), and stained with lead citrate. Images were acquired
using a Tecnai Spirit Biotwin transmission electron microscope (Thermo Fisher Scientific).
In vivo infections. C57BL/6 (wild-type) mice were bred and housed under pathogen-free conditions
in the biological research facility at The Francis Crick Institute in accordance with the Home Office UK
Animals (Scientific Procedures) Act 1986. All work was approved by the UK Home Office (project license
PDE274B7D) and The Francis Crick Institute Ethical Review Panel and conformed to European Union
directive 2010/63/EU. All mice used in this study were male and between 7 and 9 weeks old.
Mice were infected with PruΔku80, PruΔsfp1, or PruΔgra29 tachyzoites by intraperitoneal (i.p.)
injection with either 3E5 or 5E4 parasites in 200 l PBS on day 0 to assess mouse survival. Mice were
monitored and weighed regularly for the duration of the experiments.
Mass spectrometry. (i) SFP1 transfection and immunoprecipitation. A total of 2.8  106 HFFs
were seeded into a 15-cm dish 24 h before transfection with 44 g pcDNA-SFP1 using Lipofectamine
3000 (Thermo Fisher) according to the manufacturer’s instructions. At 18 h posttransfection, cells were
lysed on ice with 2 ml IP buffer (Thermo Scientific) for 30 min, passed through a 23-gauge needle, and
clarified by centrifugation. The supernatant was incubated with 60 l of polyclonal SFP1 antibody-coated
Fastflow protein G-Sepharose (GE Healthcare). Sepharose bead complexes were washed in IP buffer
followed by Tris-buffered saline, and proteins were eluted by boiling in Laemmli buffer.
(ii) In-gel digestion and LC-MS/MS. Eluted proteins were separated by SDS-PAGE until the running
front had migrated approximately 2 cm into the gel (12% NuPAGE; Invitrogen) and stained with colloidal
Coomassie (InstantBlue; Expedeon). After the excision of 8 horizontal gel slices per lane, proteins were
in-gel digested with trypsin (Promega/Pierce) using a Janus liquid-handling system (PerkinElmer). Tryptic
peptides were analyzed by liquid chromatography-mass spectrometry (LC-MS) using an Orbitrap Velos
mass spectrometer coupled to an Ultimate 3000 ultrahigh-performance liquid chromatography (uHPLC)
instrument equipped with an Easy-Spray nanosource (Thermo Fisher Scientific) and acquired in data-
dependent mode.
(iii) MS data processing and analysis. The data were searched against Toxoplasma gondii and Homo
sapiens (both UniProt) databases using the Andromeda search engine. Raw data were processed with
MaxQuant (version 1.5.2.8). Cysteine carbamidomethylation was selected as a fixed modification. Methi-
onine oxidation, acetylation of the protein N terminus, and phosphorylation (S, T, and Y) were selected
as variable modifications. The enzyme specificity was set to trypsin with a maximum of 2 missed
cleavages. The data sets were filtered on posterior error probability to achieve a 1% false-discovery rate
(FDR) on the protein, peptide, and site levels. Data were further analyzed with Perseus (version 1.5.0.9).
The data were filtered to remove common contaminants and identifications (IDs) originating from
reverse decoy sequences and identified only by site. The log10 values for peptide intensities were then
determined, and all SFP1 peptides (58% sequence coverage) were analyzed based on their modification
state. No phosphorylated peptides were found.
Tachyzoite versus bradyzoite phosphoproteomes. (i) Infection conditions. Confluent HFF mono-
layers were grown in 15-cm dishes and infected with PruΔhxgprt. For tachyzoite samples, three dishes
were infected with 1.3  107 parasites and incubated for 27 h. For bradyzoite samples, three plates were
infected with 1.1  107 parasites for 3.5 h before extensive washing and the addition of switch medium
(described above). Bradyzoite infection samples were incubated as described above for 3 days, with fresh
switch medium added daily.
(ii) Cell lysis and protein digestion. Lysis was performed in a solution containing ice-cold 8 M urea,
75 mM NaCl, and 50 mM Tris (pH 8.2) supplemented with protease (complete mini; Roche) and phos-
phatase (Phos Stop; Roche) inhibitors. Lysis was followed by sonication to reduce sample viscosity (30%
duty cycle, with three 30-s bursts, on ice). The protein concentration was measured using a bicinchoninic
acid (BCA) protein assay kit (Pierce). Lysates (1 mg each) were subsequently reduced with 5 mM DTT for
30 min at 56°C and alkylated in the dark with 14 mM iodoacetamide for 30 min at RT. Following
iodoacetamide quenching with 5 mM DTT for 15 min in the dark, the lysates were diluted with 50 mM
ammonium bicarbonate to 4 M urea and digested with LysC (Promega) for 2 to 3 h at 37°C. The lysates
were further diluted with 50 mM ammonium bicarbonate to 2 M urea and digested with trypsin
(Promega) overnight at 37°C. After digestion, samples were acidified with trifluoroacetic acid (TFA)
(Thermo Fisher Scientific) to a final concentration of 1% (vol/vol). All insoluble material was removed by
centrifugation, and the supernatant was desalted on Sep-Pak C18 cartridges (Waters).
(iii) TMT labeling. Samples were dissolved at 1 mg/ml in a solution containing 50 mM Na-HEPES (pH
8.5) and 30% (vol/vol) acetonitrile and labeled with the respective TMT reagents (Thermo Fisher
Scientific) (2.4 mg reagent/1 mg sample) for 1 h at RT. Labeling was then quenched with 0.3% hydrox-
ylamine for 15 min at RT, and samples were acidified (pH 2) with formic acid. After verification of
Young et al.















































labeling efficiency via mass spectrometry, the lysates were mixed in a 1:1 ratio, vacuum dried, and
desalted on Sep-Pak C18 cartridges.
(iv) Phosphopeptide enrichment. Desalted and vacuum-dried samples were solubilized in 1 ml of
loading buffer (80% acetonitrile, 5% TFA, 1 M glycolic acid) and mixed with 5 mg of TiO2 beads
(Titansphere, 5 m; GL Sciences Japan). Samples were incubated for 10 min with agitation, followed by
a 1-min spin at 2,000  g to pellet the beads. The supernatant was removed and used for a second round
of enrichment as explained below. Beads were washed with 150 l loading buffer, followed by two
additional washes, the first with 150 l 80% acetonitrile–1% TFA and the second with 150 l 10%
acetonitrile– 0.2% TFA. After each wash, beads were pelleted by centrifugation (1 min at 2,000  g), and
the supernatant was discarded. Beads were dried in a vacuum centrifuge for 30 min, followed by two
elution steps at high pH. For the first elution step, beads were mixed with 100 l of 1% (vol/vol)
ammonium hydroxide, and for the second elution step, beads were mixed with 100 l of 5% (vol/vol)
ammonium hydroxide. Each time, the beads were incubated for 10 min with agitation and pelleted at
2,000  g for 1 min. The two eluates were removed following each spin and subsequently pooled before
undergoing vacuum drying. The supernatant from the TiO2 enrichment was desalted on Sep-Pak C18
cartridges, and the High Select Fe-NTA phosphopeptide enrichment kit (Thermo Fisher Scientific) was
used for a second round of enrichment according to the manufacturer’s instructions.
(v) Sample fractionation and desalting. Combined TiO2 and Fe-NTA phosphopeptide eluates
(phosphoproteome) as well as 100 g of the postenrichment supernatant (total proteome) were frac-
tionated using the Pierce high-pH reversed-phase kit (Thermo Fisher Scientific) according to the
manufacturer’s instructions. The resulting fractions, 8 for each phospho- and total proteome, were taken
to dryness by vacuum centrifugation and further desalted on a stage tip using Empore C18 discs (3M).
Briefly, each stage tip was packed with one C18 disc and conditioned with 100 l of 100% methanol,
followed by 200 l of 1% TFA. The sample was loaded in 100 l of 1% TFA, washed 3 times with 200 l
of 1% TFA, and eluted with 50 l of 50% acetonitrile–5% TFA. The desalted phosphoproteome and total
proteome fractions were vacuum dried in preparation for LC-tandem MS (MS/MS) analysis.
(vi) LC-MS/MS and data processing. Samples were resuspended in 0.1% TFA and loaded onto a
50-cm Easy-Spray PepMap column (75-m inner diameter, 2-m particle size; Thermo Fisher Scientific)
equipped with an integrated electrospray emitter. Reverse-phase chromatography was performed using
the RSLC nano U3000 instrument (Thermo Fisher Scientific) with a binary buffer system (solvent A, 0.1%
formic acid and 5% DMSO; solvent B, 80% acetonitrile, 0.1% formic acid, and 5% DMSO) at a flow rate
of 250 nl/min. The samples were run on a linear gradient of 5 to 60% solvent B in 150 min, with a total
run time of 180 min, including column conditioning. The nanoscale LC (nanoLC) instrument was coupled
to an Orbitrap Fusion Lumos mass spectrometer using an Easy-Spray nanosource (Thermo Fisher
Scientific). The Orbitrap Fusion Lumos instrument was operated in data-dependent mode using 3
acquisition methods. For the phospho MS2 method, high-energy collisional dissociation (HCD) MS/MS
scans (R  50,000) were acquired after an MS1 survey scan (R  120,000) using an MS1 target of 4E5 ions
and an MS2 target of 2E5 ions. The number of precursor ions selected for fragmentation was determined
by the “Top Speed” acquisition algorithm with a cycle time of 3 s and dynamic exclusion of 60 s. The
maximum ion injection time utilized for MS2 scans was 86 ms, and the HCD collision energy was set at
38. For the phospho MS3 method, collision-induced dissociation (CID) MS/MS scans (R  30,000) were
acquired after an MS1 survey scan with the same parameters as the ones described above. The MS2 ion
target was set at 5E4, with multistage activation of neutral loss (H3PO4) enabled. The maximum ion
injection time utilized for MS2 scans was 80 ms, and the CID collision energy was set at 35. The HCD MS3
scan (R  60,000) was performed with synchronous precursor selection enabled to include up to 5 MS2
fragment ions. The ion target was 1E5, the maximum ion injection time was 105 ms, and the HCD
collision energy was set at 65. The proteome MS2 method was the same as the one for phospho MS2
with the following modification to MS2 target 5E4 ions. Acquired raw data files were processed with
MaxQuant (47) (version 1.5.2.8), and peptides were identified from the MS/MS spectra searched against
Toxoplasma gondii (ToxoDB) and Homo sapiens (UniProt) proteomes using the Andromeda (48) search
engine. TMT-based experiments in MaxQuant were performed using the “reporter ion MS2 or MS3”
built-in quantification algorithm, with the reporter mass tolerance set to 0.003 Da. Cysteine carbam-
idomethylation was selected as a fixed modification. Methionine oxidation, acetylation of the protein N
terminus, deamidation (N, Q), and phosphorylation (S, T, and Y) were selected as variable modifications.
The enzyme specificity was set to trypsin with a maximum of 2 missed cleavages. The precursor mass
tolerance was set to 20 ppm for the first search (used for mass recalibration) and to 4.5 ppm for the main
search. The “Match between runs” option was enabled for fractionated samples (time window of 0.7 min).
The data sets were filtered on posterior error probability to achieve a 1% false-discovery rate on the
protein, peptide, and site levels. Data were further analyzed as described in Results and in Data Set S1
using Microsoft Office Excel 2016 and Perseus (49) (version 1.5.0.9).
Data availability. The data behind the manuscript are freely available. The processed proteome and
phosphoproteome data are included in Data Set S1, and the raw mass spectrometry data have been
deposited to the ProteomeXchange Consortium via the PRIDE (50) partner repository with the data set
identifier PXD019729.
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